ArticleNature communications2025

Ceftazidime-avibactam use selects multidrug-resistance and prevents designing collateral sensitivity-based therapies against Pseudomonas aeruginosa.

Sara Hernando-Amado et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.